2. Academic Validation
  3. Raxibacumab

Raxibacumab

  • MAbs. 2009 Nov-Dec;1(6):531-8. doi: 10.4161/mabs.1.6.10195.
Sohini Mazumdar 1
Affiliations

Affiliation

  • 1 Genetics Graduate Program, Department of Anatomy and Cell Biology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA. [email protected]
PMID: 20068396 DOI: 10.4161/mabs.1.6.10195
Abstract

Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen. HGS is currently providing stockpiles of the agent to the US government for use in the prevention and treatment of inhalation anthrax. As of May 2009, the candidate was undergoing review by the US Food and Drug Administration. The availability of bioterrorism countermeasures has become more important since the September 2001 anthrax attacks, and development of raxibacumab is a significant advance in this area.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P9957
    98.88%, Antibody Against Bacillus Anthracis Protective Antigen